HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pientzehuang Pharmaceutical Co., Ltd. (600436.CH) 2021Q3 - Concerns Behind The  "Double Top Secret"

Guangzhou Baiyunshan Pharmaceutical Holdings (874.HK) - Conservative About the Outlook

Oral COVID-19 Antivirals and the Impact on China

Pre-IPO Chaoju Eye Care Holdings - Here Are the Strength and the Concerns

New Horizon Health (6606.HK) - Still Has a Long Way to Go

Pre-IPO Angelalign Technology - Promising Market but Full of Challenges

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Bottom-Up

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. / Equity Bottom-Up

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (600436 CH)

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

<p><a href="https://www.smartkarma.com/entities/zhangzhou-pientzehuang-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:15709:1" rel="noopener">Zhangzhou Pientzehuang Pharmaceutical Co (600436 CH)</a> recently released the performance report in 2020. For the whole year 2020, the revenue was RMB6.507 billion, up 13.72% YoY. Net income attributed to shareholders was RMB1.67 billion, up 21.27% YoY. Net income after deducting non-recurring gains and losses was RMB1.613 billion, up 19.11% YoY. In 2020Q4, the Company's revenue was RMB1.381 billion, up 4.11% YoY. Net income attributed to shareholders was RMB338 million, up 27.31% YoY. Net income after deducting non-recurring gains and losses was RMB292 million, up 16.36% YoY. The Company's performance was in line with the market expectation.</p>

Zhangzhou Pientzehuang Pharmaceutical Co (600436 CH) recently released the performance report in 2020. For the whole year 2020, the revenue was RMB6.507 billion, up 13.72% YoY. Net income attributed to shareholders was RMB1.67 billion, up 21.27% YoY. Net income after deducting non-recurring gains and losses was RMB1.613 billion, up 19.11% YoY. In 2020Q4, the Company's revenue was RMB1.381 billion, up 4.11% YoY. Net income attributed to shareholders was RMB338 million, up 27.31% YoY. Net income after deducting non-recurring gains and losses was RMB292 million, up 16.36% YoY. The Company's performance was in line with the market expectation.

Tong Ren Tang Technologies Co, Ltd. (1666 HK)

Pientzehuang Pharmaceutical (600436.CH) - The Only "Double Top Secret" Traditional Chinese Medicine